Overview
Financials
Units: $M (per-share in $, ratios in %)Revenue & profit
Margins
Valuation
Multiples at each fiscal year end (annual) and current (TTM)Valuation history
Segments
Revenue breakdown (annual, $B). Segments depend on each year’s disclosure.By product
By region
Dividends & earnings
Annual dividend per share ($, split-adjusted)
EPS (diluted), last 16 quarters ($)
Company info
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.